Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT ‐1 and SURMOUNT ‐2 Trials
Authors' conclusion
In this post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials, tirzepatide-treated participants with obesity or overweight in both ER and non-ER groups achieved clinically meaningful weight reduction and improvements in CRPs at Week 72. However, ERs experienced greater weight reduction and improvements in CRP than non-ERs, with a comparable gastrointestinal tolerability profile.
Study context
- Population
- Tirzepatide-treated participants with obesity or overweight, without (SM-1) or with T2D (SM-2)SM-1 n = 1775
- Participants
- 2,384 participants
- Comparison
- Early responders vs nonearly responders to tirzepatide
Methodological detailspost hoc exploratory analyses, phase 3, multicentre, placebo-controlled, double-blind
- Post hoc exploratory analyses
- Phase 3
- Multicentre
- Placebo-controlled
- Double-blind
Primary result
As reported in the abstract
Weight reduction and CRPs, including HbA1c · baseline to Week 72
- Clinically meaningful weight reduction and improvements in cardiometabolic risk parameters (CRPs), including HbA1c, with significantly greater improvements in early responders (ERs) vs non-ERs
- Efficacy estimand
Further findings
Baseline characteristics
- ERs were more likely to be female, White and to have lower baseline HbA1c
Safety
- Pattern, severity and time course of gastrointestinal events similar between groups
Original publication
Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT ‐1 and SURMOUNT ‐2 Trials. Diabetes Obes Metab. Published 25 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →